Sandoz's Carol Lynch Highlights Decade Of Biosimilar Dominance And Plans For Many More Winning Years
Executive Summary
2016 marks the 10 year anniversary of the first biosimilar approval in Europe, Sandoz Inc.'s Omnitrope (somatropin), but only the first anniversary for approval of a biologic copycat drug in the US – a country that has been slow to embrace the concept. Sandoz's global head of biopharmaceuticals and oncology, Carol Lynch, explains to Scrip how the biosimilars market has developed over the last decade and what the biggest challenges have been along the way.